tirzepatide vs dulaglutide in T2D with ASCVD | Scott Isaacs, MD, FACP, FACE posted on the topic Tirzepatide vs. Dulaglutide: Cardiovascular Outcomes

Were Here for You If you have questions about your medication, GLP-1 dosing, supplements, or safe storage practices, were just a call or message away

Festina Lente, a contractor for Novo Nordisk, provided methodological support

However, the principal strength of this study was the long-term observation, providing the first insights into a potential novel strategy for partially overcoming adaptive mechanisms following the cessation of semaglutide-induced weight loss in insulin-resistant populations

Drug Class Insights How the Long-acting GLP-1 Agonists Segment Led the GLP-1 Market

That molecular complexity means it is inherently fragile